PMID- 38097011 OWN - NLM STAT- MEDLINE DCOM- 20240216 LR - 20240216 IS - 1878-1780 (Electronic) IS - 1262-3636 (Linking) VI - 50 IP - 1 DP - 2024 Jan TI - Reduction of circulating methylglyoxal levels by a Mediterranean diet is associated with preserved kidney function in patients with type 2 diabetes and coronary heart disease: From the CORDIOPREV randomized controlled trial. PG - 101503 LID - S1262-3636(23)00085-X [pii] LID - 10.1016/j.diabet.2023.101503 [doi] AB - AIM: Advanced glycation end products (AGEs) play a role in kidney disease in type 2 diabetes mellitus (T2DM). However, there have been no prior controlled clinical trials examining the effects of specific diets on AGE metabolism and their impact on kidney function. Our aim was to assess whether modulating AGE metabolism resulting in reduced AGEs levels, after consumption of two healthy diets, could delay kidney function decline in patients with T2DM and coronary heart disease (CHD). METHODS: T2DM patients (540 out of 1002 patients from the CORDIOPREV study), with estimated glomerular filtration rate (eGFR) >/= 30 ml/min/1.73 m(2), were classified based on their baseline kidney function: normal eGFR (>/= 90 ml/min/1.73 m(2)), mildly decreased eGFR (60- < 90 ml/min/1.73 m(2)) and moderately decreased eGFR (<60 ml/min/1.73 m(2)). Serum AGE levels, methylglyoxal (MG) and N-carboximethyllysine (CML), and gene expression related to AGE metabolism (AGER1, RAGE, and GloxI mRNA) were measured before and after 5-years of dietary intervention (a Mediterranean diet or a low-fat diet). RESULTS: Mediterranean diet produced a lower declined of eGFR compared to the low-fat diet only in patients with mildly decreased eGFR (P = 0.035). Moreover, Mediterranean diet was able to decrease MG levels and increase GloxI expression in normal and mildly decreased eGFR patients (all P < 0.05). One standard deviation increment of MG levels after dietary intervention resulted in a 6.8-fold (95 % CI 0.039;0.554) higher probability of eGFR decline. CONCLUSION: Our study showed that lowering circulating AGE levels, specifically MG, after following a Mediterranean diet, might be linked to the preservation of kidney function, evidenced by a decreased decline of eGFR in T2DM patients with CHD. Patients with mildly decreased eGFR could potentially benefit more from AGE reduction in maintaining kidney function. CI - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Gutierrez-Mariscal, Francisco M AU - Gutierrez-Mariscal FM AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Podadera-Herreros, Alicia AU - Podadera-Herreros A AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Alcala-Diaz, Juan F AU - Alcala-Diaz JF AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Cardelo, Magdalena P AU - Cardelo MP AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Arenas-de Larriva, Antonio P AU - Arenas-de Larriva AP AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Cruz-Ares, Silvia de la AU - Cruz-Ares S AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Torres-Pena, Jose D AU - Torres-Pena JD AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Luque, Raul M AU - Luque RM AD - CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain; Department of Cell Biology, Physiology and Immunology, University of Cordoba, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain. FAU - Perez-Martinez, Pablo AU - Perez-Martinez P AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Delgado-Lista, Javier AU - Delgado-Lista J AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. FAU - Lopez-Miranda, Jose AU - Lopez-Miranda J AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. Electronic address: jlopezmir@uco.es. FAU - Yubero-Serrano, Elena M AU - Yubero-Serrano EM AD - Unidad de Gestion Clinica Medicina Interna, Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba, Reina Sofia University Hospital, University of Cordoba, Cordoba 14004, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain. Electronic address: elena.yubero@imibic.org. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20231212 PL - France TA - Diabetes Metab JT - Diabetes & metabolism JID - 9607599 RN - 722KLD7415 (Pyruvaldehyde) SB - IM MH - Humans MH - Child, Preschool MH - *Diabetes Mellitus, Type 2 MH - Pyruvaldehyde MH - *Diet, Mediterranean MH - Kidney MH - *Coronary Disease OTO - NOTNLM OT - Advanced glycation end products OT - Dietary strategy OT - Kidney function OT - Mediterranean diet OT - Methylglyoxal OT - Type 2 diabetes COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/12/15 00:43 MHDA- 2024/02/16 06:43 CRDT- 2023/12/14 19:25 PHST- 2023/10/13 00:00 [received] PHST- 2023/11/29 00:00 [revised] PHST- 2023/12/03 00:00 [accepted] PHST- 2024/02/16 06:43 [medline] PHST- 2023/12/15 00:43 [pubmed] PHST- 2023/12/14 19:25 [entrez] AID - S1262-3636(23)00085-X [pii] AID - 10.1016/j.diabet.2023.101503 [doi] PST - ppublish SO - Diabetes Metab. 2024 Jan;50(1):101503. doi: 10.1016/j.diabet.2023.101503. Epub 2023 Dec 12.